Clinical trials: Covid19
Covid-19
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease
- Trial name
- NCT04400058
- Testing
- Octagam 10%, Saline Solution
- Where
- 22 sites in United States, Russia and 1 more
- Volunteers
- 207 people
- Sponsor
- Octapharma
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Viral Respiratory Tract Infection
Safety and Tolerability of Single and Multiple Doses of Neumifil
This is a Phase 1, single-centre, randomised, placebo-controlled first in human study in healthy subjects. The study will assess the safety and tolerability of single-ascending (Part A) and multiple-ascending (Part B) doses of…
- Trial name
- NCT05093530
- Testing
- Neumifil
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pneumagen Ltd.
Covid19
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy…
- Trial name
- COSMIC (NCT05280717)
- Testing
- sotrovimab
- Where
- 10 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
- Trial name
- NCT04432298
- Testing
- Pamrevlumab
- Where
- 4 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kyntra Bio
COVID-19
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for…
- Trial name
- EMPATHY (NCT04828161)
- Testing
- ensovibep
- Where
- 48 sites in United States, Hungary and 3 more
- Volunteers
- 407 people
- Sponsor
- Novartis Pharmaceuticals
Bioequivalence
Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting…
- Trial name
- Favipiravir (NCT04406194)
- Testing
- FAVICOVIR 200 mg Film Tablet, AVIGAN 200 mg Film Tablets
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Atabay Kimya Sanayi Ticaret A.S.
COVID-19
Drug Use Investigation of COMIRNATY Intramuscular Injection
Post-marketing study, Chotor study of COMIRNATY vaccenees followed for 11months. Serious adverse events and COVID-19 observed during the follow-up period will be collected, and the long-term safety of this product will be…
- Trial name
- NCT04815031
- Testing
- BNT162b2
- Where
- Japan
- Volunteers
- 14,570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Stress, Psychological, Loneliness
Ecological Momentary Assessment and Text Message Intervention for Stress Management
Feasibility and acceptability of an Ecological Momentary Assessment (EMA) compared with an EMA plus automated text message intervention for stress management
- Conditions
- Stress, Psychological, Loneliness, Covid19, Stress
- Trial name
- NCT04907942
- Testing
- EMA + EMA and FACE Stress, EMA Alone
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Click Therapeutics, Inc.
Coronavirus Disease (COVID-19)
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
The primary objective of this study is to evaluate the safety and tolerability of V590 versus placebo and to assess the immunogenicity of V590 on Day 28.
- Trial name
- NCT04569786
- Testing
- V590
- Where
- 7 sites in United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Covid-19 Testing
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab) on samples that are self-collected; and to perform…
- Trial name
- NCT04926779
- Testing
- Biozek Covid-19 Antigen Rapid Test (Saliva)
- Where
- 2 sites in United States
- Volunteers
- 185 people
- Sponsor
- Mach-E B.V.
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
COVID-19
Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
This is a randomized, double-blind, placebo-controlled study of camostat mesilate in ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.
- Trial name
- NCT04583592
- Testing
- Camostat Mesilate
- Where
- 21 sites in United States
- Volunteers
- 295 people
- Sponsor
- Sagent Pharmaceuticals Inc.
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems
COVID-19 Infection
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, Acute respiratory…
- Trial name
- NCT04346615
- Testing
- Zavegepant (BHV-3500)
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Pfizer
Coronavirus Infection
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
- Trial name
- NCT04442230
- Testing
- NasoVAX
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Altimmune, Inc.